Overview

A Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of S-217622 in Participants With Renal Impairment and Healthy Participants

Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to measure the PK, safety, and tolerability of S-217622 in participants with mild, moderate, or severe renal impairment and in those with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Shionogi